Teva Q2 2021: Revenue $3.9B, GAAP EPS $0.19, Non-GAAP EPS $0.59; guides revenue lower

TEVA PHARMACEUTICAL INDUSTRIES LTD

2021-Q2 EPS reported $0.26 revenue$7,892,000,000

Revenue of $3.9B (up 1% YoY); GAAP diluted EPS $0.19 (vs $0.13 Q2 2020); Non-GAAP diluted EPS $0.59 (vs $0.55).
Net debt reduced by $500M to $22.7B; operating cash flow $218M, free cash flow $625M.
2021 revenue outlook cut to $16.0-16.4B (prior $16.4-16.8B) citing COVID impact; all other guidance reaffirmed: adj. EBITDA $4.8-5.1B, EPS $2.50-2.70, FCF $2.0-2.3B.
AUSTEDO sales grew YoY; AJOVY net sales $70M worldwide; Truxima US market share reached 25%.
R&D expenses $248M (GAAP), increased 10% YoY, driven by respiratory, biosimilar projects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.